Stock Analysis
Precision BioSciences, Inc. (DTIL) Stock Analysis
Precision BioSciences, Inc. (DTIL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Precision BioSciences, Inc. (DTIL) currently has an AIQ Score of 49/100, indicating a neutral setup. Value is the strongest factor at 60/100. Momentum is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
DTIL at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $7.17 |
| AIQ Score | 49/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $98.01M |
| P/E Ratio | -2.6 |
| Forward P/E | — |
| EPS | -$1.26 |
| Revenue TTM | $0 |
| Dividend Yield | 0.00% |
| Beta | 1.23 |
| Volume | 191.4K |
| 52-week range | $3.53-$9.62 |
| RSI 14 | 9.62 |
| 50-Day SMA | $7.82 |
| 200-Day SMA | $6.20 |
| Analyst Price Target | $20.00 |
| Next Earnings | Nov 2, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
DTIL
OverviewDTIL Stock Analysis Summary
Precision BioSciences, Inc. (DTIL) currently has an AIQ Score of 49/100, indicating a neutral setup. Value is the strongest factor at 60/100. Momentum is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, DTIL has AIQ Score of 49/100 with Value base of 60/100 and fading Momentum at 31/100. Wait for component alignment before adding exposure.
Value (60/100) leads while Momentum (31/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.97% stock move · DTIL classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is DTIL Bullish or Bearish Right Now?
DTIL currently has a neutral overall setup. Value is the strongest factor at 60/100, while Momentum is weakest at 31/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +178.94% upside from the latest quote.
- - Momentum is weak at 31/100.
- - Technical consensus has more sell votes than buy votes (32 vs 11).
Current Consensus
DTIL's Technical Analysis Consensus is currently Sell, with 11 buy, 2 neutral, and 32 sell votes. DTIL's 14-day RSI is 9.62, which places the stock in an oversold momentum range. DTIL's beta is 1.23, indicating greater market sensitivity than the broad market.
What Changed in DTIL?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the DTIL Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
DTIL Decision Framework
Public evidence layers, setup checks, and risk context for Precision BioSciences, Inc..
Precision BioSciences, Inc. (DTIL) Stock Analysis
Precision BioSciences, Inc. has an AIQ Score of 49/100 in a Neutral regime. Value is strongest at 60/100. Beta is 1.23, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | DTIL is in a Neutral AIQ regime with score 49/100. |
| Signal Conflict | The primary conflict is that value leads at 60/100 while momentum lags at 31/100. |
| Factor Evidence | Momentum 31/100 · Value 60/100 · Quality 51/100 · Risk 51/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 60/100.
Momentum is 31/100 and RSI (14) is 9.6.
DTIL is in a Neutral regime at 49/100.
Risk factor is 51/100 with beta 1.23 and annual volatility 72.1%.
Current conflict: value leads at 60/100 while momentum lags at 31/100.
DTIL Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
DTIL Fundamentals
DTIL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
DTIL Technical Analysis
DTIL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
DTIL Stock Catalysts
Track DTIL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
DTIL Dividend Analysis
DTIL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
DTIL Financial Data
DTIL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
DTIL Risk Analysis
DTIL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
DTIL Stock News
DTIL stock news, market tone, recent headlines, and catalyst context.
DTIL vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: DTIL · EDIT · FATE · FOLD · IBRX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| DTIL Current stock | 49/100 | 60/100 | 31/100 | 51/100 | 0.8 | 72.10% | Current |
| EDIT Editas Medicine | 41/100 | 34/100 | 38/100 | 39/100 | 0.44 | 85.13% | DTIL vs EDIT |
| FATE Fate Therapeutics | 34/100 | 34/100 | 47/100 | 34/100 | 1.29 | 96.18% | DTIL vs FATE |
| FOLD Amicus Therapeutics | 41/100 | 35/100 | — | 66/100 | 2.61 | 44.15% | DTIL vs FOLD |
| IBRX ImmunityBio | 60/100 | 34/100 | 63/100 | 28/100 | 1.53 | 104.47% | DTIL vs IBRX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching DTIL
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for DTIL
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
DTIL Stock FAQ
What is DTIL stock price today?
Precision BioSciences, Inc.'s current stock price is $7.17. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is DTIL bullish or bearish right now?
DTIL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is DTIL's market cap?
DTIL's market cap is $98.01M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is DTIL's current P/E ratio?
DTIL's current P/E ratio is -2.6 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is DTIL's RSI?
DTIL's 14-day RSI is 9.62 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is DTIL above its 50-day and 200-day moving averages?
DTIL is -8.34% from its 50-day SMA and 15.64% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is DTIL's next earnings date?
DTIL's next earnings date is currently listed as Nov 2, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does DTIL pay a dividend?
DTIL's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.